AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: GlobeNewswire
Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019Etokimab Phase 2a Severe Eosinophilic Asthma Data to be Presented at the 2019 EAACI CongressIND Filing for New Wholly-owned Anti-inflammatory Program Anticipated in Second Half of 2019 SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the first quarter ended March 31, 2019 and provided pipeline updates. “2019 is set to be an important year for AnaptysBio, with multiple top-line data readouts from our wholly-owned pipeline, initiation of a new Phase 2b trial of etokimab in eosinophilic asthma and submission of an IND for our next development candidate in our wholly-owned pipeline,” said Hamza Suria, president and chief executive officer of AnapytsBio. “We look forward to advancing ea
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.MarketBeat
- Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week [Yahoo! Finance]Yahoo! Finance
- AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $56.00 price target on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $30.00 to $28.00. They now have a "neutral" rating on the stock.MarketBeat
ANAB
Earnings
- 3/11/24 - Beat
ANAB
Sec Filings
- 3/26/24 - Form 4
- 3/11/24 - Form S-8
- 3/11/24 - Form 10-K
- ANAB's page on the SEC website